This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Ayala Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Ken Berlin
Chief executive officer
n/a
Total compensation
CEO salary percentage
n/a
CEO tenure
2.3yrs
CEO ownership
n/a
Management average tenure
2.3yrs
Board average tenure
2.3yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Ken Berlin's remuneration changed compared to Ayala Pharmaceuticals's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2023
US$736k
US$693k
-US$48m
Compensation vs Market: Insufficient data to establish whether Ken's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.
CEO
Ken Berlin (61 yo)
2.3yrs
Tenure
US$736,290
Compensation
Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer & Director at Ayala Pharmaceuticals, Inc. (Formerly known as Advaxis, Inc.) since October 19, 2023. He served as...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Kenneth Berlin
CEO, President & Director
2.3yrs
US$736.29k
no data
Irit Klipper-Avni
Vice President of Human Resources
2.3yrs
no data
no data
Dana Gelbaum
GM & Chief Business Officer
2.3yrs
no data
no data
2.3yrs
Average Tenure
Experienced Management: ADXS's management team is considered experienced (2.3 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Kenneth Berlin
CEO, President & Director
2.3yrs
US$736.29k
no data
Roni Appel
Independent Director
2.3yrs
no data
no data
Murray Goldberg
Independent Director
2.3yrs
no data
no data
David Sidransky
Chairman
2.3yrs
no data
no data
Robert Jay Spiegel
Independent Director
2.3yrs
no data
no data
Pini Orbach
Director
2.3yrs
no data
no data
Vered Bisker-Leib
Independent Vice Chairman
2.3yrs
no data
no data
Yuval Cabilly
Director
2.3yrs
no data
no data
2.3yrs
Average Tenure
60.5yo
Average Age
Experienced Board: ADXS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/02/05 13:39
End of Day Share Price
2026/02/03 00:00
Earnings
2023/12/31
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ayala Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.